![腾博会官网·[中国]-诚信为本,专业服务!
制药英文站](http://zhengzhoujiaobanji.com/userfiles/images/banner/sinologo.png)
Investors
Information Disclosure
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 20232024.01.02
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"2024.01.02
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.01.02
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIAL FOR INNOVATIVE MEDICINE "TRD205 (AT2R RECEPTOR ANTAGONIST)" TABLET2023.12.27
-
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF ANLOTINIB (A CATEGORY I NNOVATIVE DRUG) COMBINED WITH CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA2023.12.22
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.22
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.21
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.19